Showing 1 - 5 results of 5 for search 'Hans Prenen', query time: 0.01s
Refine Results
-
1
Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assays by Christophe Deben, Edgar Cardenas De La Hoz, Felicia Rodrigues Fortes, Maxim Le Compte, Sofie Seghers, Steve Vanlanduit, Hendrik Vercammen, Bert Van Den Bogert, Nelson Dusetti, Abraham Lin, Geert Roeyen, Marc Peeters, Hans Prenen, Filip Lardon, Evelien Smits
Published 2024-12-01Get full text
Article -
2
PHD1 regulates p53‐mediated colorectal cancer chemoresistance by Sofie Deschoemaeker, Giusy Di Conza, Sergio Lilla, Rosa Martín‐Pérez, Daniela Mennerich, Lise Boon, Stefanie Hendrikx, Oliver DK Maddocks, Christian Marx, Praveen Radhakrishnan, Hans Prenen, Martin Schneider, Johanna Myllyharju, Thomas Kietzmann, Karen H Vousden, Sara Zanivan, Massimiliano Mazzone
Published 2015-08-01Get full text
Article -
3
A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours by Yasutoshi Kuboki, Hendrik-Tobias Arkenau, Vivek Subbiah, Timothy Price, Gerald Falchook, Hans Prenen, Rafal Dziadziuszko, Hansen Wong, Iwona Lugowska, Daniel Tan, Weibing Shi, Ryota Shibaki, Min Hee Hong, Sant P Chawla, Jose G Monzon, Mun Hui, Caio Max Rocha Lima, Kejia Wang, Antreas Hindoyan, Mira Kistler
Published 2025-05-01Get full text
Article -
4
Cracking the code of a correlate of protection against SARS-CoV-2 breakthrough infection in cancer patients by Yana Debie, Irene Garcia-Fogeda, Lander Willem, Ella Roelant, Lise Verbruggen, Greetje Vanhoutte, Lieselot Croes, Christof Vulsteke, Wim Demey, Willem Lybaert, Marianne Hanssens, Alain Bols, Johan Van ongeval, Ann De Becker, Hilde Jansens, Maria E. Goossens, Annelies Janssens, Hans Prenen, Sébastien Anguille, Marc Peeters, Peter A. van Dam, Niel Hens, Steven Abrams, Timon Vandamme
Published 2025-03-01Get full text
Article -
5
A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC) by Francesca Aroldi, Elena Elez, Thierry André, Geraldine Perkins, Hans Prenen, Vlad Popovici, Peter Gallagher, Jennifer Houlden, Linda Collins, Corran Roberts, Christian Rolfo, Federica Di Nicolantonio, Margaret Grayson, Ruth Boyd, Karolien Bettens, Jurgen Delfavero, Victoria Coyle, Mark Lawler, Hajrah Khawaja, Pierre Laurent-Puig, Manuel Salto-Tellez, Tim S. Maughan, Josep Tabernero, Richard Adams, Robert Jones, Bryan T. Hennessy, Alberto Bardelli, Marc Peeters, Mark R. Middleton, Richard H. Wilson, Sandra Van Schaeybroeck, on behalf of the MErCuRIC Trial Consortium
Published 2025-04-01Get full text
Article